Home » Accord Healthcare Ireland launch ORGOVYX®▼ (relugolix 120 mg) — oral androgen deprivation therapy for prostate cancer

Go Back

Accord Healthcare Ireland launch ORGOVYX®▼ (relugolix 120 mg) — oral androgen deprivation therapy for prostate cancer

October 2023

Accord Healthcare has launched its latest oncology treatment, ORGOVYX^®▼ (relugolix) 120 mg which comes in pack size of 30 film-coated tablets. Relugolix is the first and only oral androgen deprivation therapy (ADT) for advanced hormone-sensitive prostate cancer.

Relugolix was granted Marketing Authorisation by the European Medicines Agency on 29 April 2022. In May 2022, Accord was selected by Myovant Sciences to commercialise this product across Europe (European Economic Area, United Kingdom, Switzerland and Turkey). Please refer to the Summary of Product Characteristics (SPC) for further information. The SPC will be available at hpra.ie and for healthcare professionals at accord-healthcare.ie. Orgovyx® will be available from both full-line wholesalers from launch. For further information contact Accord in Cork on 021 461 9040.